A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)
Phase of Trial: Phase IV
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms ENTERPRISE
- Sponsors Takeda
- 08 Jun 2017 Planned number of patients changed from 126 to 100.
- 08 Jun 2017 Planned End Date changed from 5 Jun 2018 to 9 Mar 2019.
- 08 Jun 2017 Planned primary completion date changed from 30 Jan 2018 to 3 Nov 2018.